<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-20-13</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-20-2-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Infectious Diseases</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Trial of Immune Globulin in Infant Botulism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>02</month>
<year>2006</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>02</month>
<year>2016</year>
</pub-date>
<volume>20</volume>
<issue>2</issue>
<fpage>13</fpage>
<lpage>13</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 2006 The Author(s)</copyright-statement>
<copyright-year>2006</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.1056/NEJMoa051926" vol="354" page="462">
<article-title>Human botulism immune globulin for the treatment of infant botulism</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>A 5-year, randomized, double-blind, placebo-controlled trial of the orphan drug Human Botulism Immune Globulin Intravenous (BIG-IV) in 122 infants in California with confirmed infant botulism (75 caused by type A Clostridium botulinum toxin, and 47 by type B toxin) was conducted at the California Department of Health Services, Richmond, CA; National Botulism Surveillance and Reference Laboratory, CDC and P, Atlanta; and Division of Biostatistics, University of California, Berkeley.</p>
</abstract>
<kwd-group>
<kwd>Human Botulism Immune Globulin Intravenous</kwd>
<kwd>Infant Botulism</kwd>
<kwd>Werdnig Hoffman</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>A 5-year, randomized, double-blind, placebo-controlled trial of the orphan drug Human Botulism Immune Globulin Intravenous (BIG-IV) in 122 infants in California with confirmed infant botulism (75 caused by type A <italic>Clostridium botulinum</italic> toxin, and 47 by type B toxin) was conducted at the California Department of Health Services, Richmond, CA; National Botulism Surveillance and Reference Laboratory, CDC and P, Atlanta; and Division of Biostatistics, University of California, Berkeley. Eligible infants had acute flaccid paralysis consistent with infant botulism and had been hospitalized for &#x003C;3 days. Infants treated with BIG-IV showed significant reductions in hospital stay, time in intensive care, duration of mechanical ventilation, duration of tube or intravenous feeding, and hospital charges. In a 6-year nation-wide, open-label study, infants treated with BIG-IV within 7 days of admission had a mean hospital stay of 2.2 weeks, and early treatment shortened the length of stay significantly more than later treatment. No serious adverse events were attributable to BIG-IV. [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<p>COMMENT. The diagnosis of infant botulism may be difficult and requires a high index of suspicion. One infant in the trial who died 5 months after receiving placebo was subsequently found to have Werdnig Hoffman disease. The authors comment that infant botulism was suspected at admission in only half of the patients enrolled in the randomized trial. Three-quarters of the infants needed intensive care, and half needed mechanical ventilation. Serious complications included nosocomial C <italic>difficile</italic> infection with pseudomembranous colitis and toxic shock in one infant, and one patient required surgical repair of tracheal stenosis after intubation. BIG-IV has a half-life of 28 days and will neutralize for 6 months the botulinum toxin absorbed from the colon of an infant. [<xref ref-type="bibr" rid="CIT0002">2</xref>]</p>
<p>Three infants with a relapsing form of infant botulism (IB) were reported from the Children's Hospital of Philadelphia [<xref ref-type="bibr" rid="CIT0003">3</xref>]. None had been re-exposed to honey or breast milk. Honey has been implicated in several cases in the USA [<xref ref-type="bibr" rid="CIT0004">4</xref>]. Over 600 cases of IB were reported in the US in a 14 year period, the disease being endemic in California, Utah, and Pennsylvania. The disease is rare in the United Kingdom, only 2 cases reported up to 1989 [<xref ref-type="bibr" rid="CIT0005">5</xref>]. Differential diagnoses include neonatal myasthenia gravis, infectious polyneuritis, congenital myopathy, infantile spinal muscular atrophy, and organic phosphate intoxication. Aminoglycoside antibiotics may exacerbate the paralysis and hypotonia. Most patients with IB recover, but recovery appears to be accelerated and complications lessened by use of BIG-IV.</p>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnon</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Schechter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maslanka</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Jewell</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Hatheway</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>Human botulism immune globulin for the treatment of infant botulism</article-title>
<source>N Engl J Med</source>
<month>Feb</month>
<day>2</day>
<year>2006</year>
<volume>354</volume>
<issue>5</issue>
<fpage>462</fpage>
<lpage>471</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa051926</pub-id>
<pub-id pub-id-type="pmid">16452558</pub-id>
</element-citation>
</ref>
<ref id="CIT0002">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Clay</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Arnon</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Diagnosis and management of infant botulism</article-title>
<source>Am J Dis Child</source>
<month>Jun</month>
<year>1979</year>
<volume>133</volume>
<issue>6</issue>
<fpage>586</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1001/archpedi.1979.02130060026004</pub-id>
<pub-id pub-id-type="pmid">375717</pub-id>
</element-citation>
</ref>
<ref id="CIT0003">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glauser</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Maguire</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Sladky</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Relapse of infant botulism</article-title>
<source>Ann Neurol</source>
<month>Aug</month>
<year>1990</year>
<volume>28</volume>
<issue>2</issue>
<fpage>187</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410280214</pub-id>
<pub-id pub-id-type="pmid">2221848</pub-id>
</element-citation>
</ref>
<ref id="CIT0004">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnon</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Infant botulism</article-title>
<source>Annu Rev Med</source>
<year>1980</year>
<volume>31</volume>
<fpage>541</fpage>
<lpage>560</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.me.31.020180.002545</pub-id>
<pub-id pub-id-type="pmid">6772092</pub-id>
</element-citation>
</ref>
<ref id="CIT0005">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Hinde</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Westmoreland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Infantile botulism</article-title>
<source>Arch Dis Child</source>
<month>Jun</month>
<year>1989</year>
<volume>64</volume>
<issue>6</issue>
<fpage>871</fpage>
<lpage>872</lpage>
<pub-id pub-id-type="doi">10.1136/adc.64.2.196</pub-id>
<pub-id pub-id-type="pmid">2673055</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>